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While the VGF-derived TLQP peptides have been shown to prevent neuronal apoptosis, 
and to act on synaptic strengthening, their involvement in Amyotrophic Lateral Sclerosis 
(ALS) remains unclarified. We studied human ALS patients’ plasma (taken at early to late 
disease stages) and primary fibroblast cultures (patients vs controls), in parallel with 
SOD1-G93A transgenic mice (taken at pre-, early- and late symptomatic stages) and the 
mouse motor neuron cell line (NSC-34) treated with Sodium Arsenite (SA) to induce 
oxidative stress. TLQP peptides were measured by enzyme-linked immunosorbent 
assay, in parallel with gel chromatography characterization, while their localization were 
studied by immunohistochemistry. In controls, TLQP peptides, including forms 
compatible with TLQP-21 and -62, were revealed in plasma and spinal cord motor 
neurons, as well as in fibroblasts and NSC-34 cells. TLQP peptides were reduced in ALS 
patients’ plasma starting in the early disease stage (14% of controls) and remaining so at 
the late stage (16% of controls). In mice, a comparable pattern of reduction was shown 
(vs wild type), in both plasma and spinal cord already in the pre-symptomatic phase 
(about 26% and 70%, respectively). Similarly, the levels of TLQP peptides were reduced 
in ALS fibroblasts (31% of controls) and in the NSC-34 treated with Sodium Arsenite 
(53% of decrease), however, the exogeneous TLQP-21 improved cell viability (SA 
treated cells with TLQP-21, vs SA treated cells only: about 83% vs. 75%). Hence, TLQP 
peptides, reduced upon oxidative stress, are suggested as blood biomarkers, while 


















LIST OF ABBREVIATIONS      
ALS: Amyotrophic Lateral Sclerosis  
ALSFRS-R: ALS Functional Rating Scale-Revised 
C3AR: complement component 3a receptor 1 
gC1q-R: receptor for the globular heads of c1q  
DMEM: Dulbecco’s modified Eagle’s medium 
EDTA: ethylenediaminetetraacetic acid 
ELISA: enzyme-linked immunosorbent assay  
ER: endoplasmic reticulum   
MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide  
NSC-34: mouse motor neuron-like hybrid cell line  
PBS: phosphate buffer saline  
PIC: protease inhibitor cocktail  
PFA: paraformaldehyde 
SA: Sodium Arsenite  
SOD1: superoxide dismutase 1 
VAChT: vesicular acetylcholine transporter 
TARDBP: TAR DNA Binding Protein
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INTRODUCTION 
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease 
characterized by neuronal degeneration in frontal cortex, brainstem and spinal cord. 
Virtually all muscles are gradually affected, with difficulties in speaking, swallowing and 
breathing, and death ensues 3 to 5 years after appearence of the first symptoms. 
Currently, no treatment is effective in stopping the progression of the disease, nor is any 
early diagnostic test available. While the aetiology of ALS is unknown, mutations of the 
superoxide dismutase 1 (SOD1) gene, or of the TARDBP (TAR DNA Binding Protein) 
gene have been hypothesized as common causes (Chiò et al., 2011; Zarei et al., 2015). 
In fact, oxidative stress, characterized by an altered equilibrium between the production 
of reactive oxygen species (free radicals) and antioxidant reactions, has been related to 
motor neuron degeneration in ALS (Bergeron, 1995; Robberecht, 2000).  TLQP peptides 
are a family of peptides derived from the VGF (non acronymic) precursor protein, some 
of these originally identified in rat brain (Trani et al., 2002). They share a common N-
terminal “TLQP” (Thr-Leu-Gln-Pro) amino acid sequence, are cleaved from the primary 
VGF product at the specific R-P-R (Arg-Pro-Arg) processing site found at rat/mouse 
VGF553–555 (VGF551-553 in human), and variably extend to the VGF precursor C-terminus 
(Brancia et al., 2010). In the brain, TLQP peptides appear to show a restricted 
localization compared to other VGF derived peptides, including a subpopulation of 
hypothalamic neurons projecting to a discrete area of median eminence (Brancia et al., 
2010; Noli et al., 2014). Recently, a differential expression of several TLQP peptides was 
reported in the Syberian hamster brain. Namely, TLQP-21 (21 amino acid in length, rat 
VGF556–576) was well represented in both hypothalamus and cortex while the longer form 
TLQP-62 (rat VGF556–617 encompassing the VGF precursor’s C-terminus) was abundant 
in cortex, and less expressed in hypothalamus (Noli et al., 2015). TLQP peptides were 
also found in hypothalamic-pituitary axis and plasma, differently expressed during the 
oestrous cycle phases (Noli et al., 2014) as well as in several peripheral locations 
including adrenal and stomach, changing in condition of stress and upon fasting, 
respectively (D’Amato et al., 2008; Brancia et al., 2010). Additional molecular forms 
compatible with predicted TLQP-30 and TLQP-42 peptides were revealed in certain 
endocrine organs (Cocco et al., 2007, Brancia et al., 2010) but have not been further 
studied so far. In human plasma, TLQP peptides were upregulated upon hyperglycaemia, 
and down-regulated in obese subjects (D’Amato et al., 2015). As to bioactivity and 
possible role/s, TLQP-21 has been shown to be involved in the regulation of metabolic 
mechanisms (Bartolomucci et al., 2006; Jethwa et al., 2007; Lewis et al., 2017), 
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reproduction (Aguilar et al., 2013; Noli et al., 2014), chronic stress (Razzoli et al., 2012) 
and inflammatory pain (Rizzi et al., 2008). The same peptide prevented apoptosis of rat 
cerebellar granules upon serum and potassium deprivation, with modulation of kinase 
phosphorylation (Severini et al., 2008). Also, it protected human umbilical vein 
endothelial cells against high-glucose-induced apopotosis, by enhancing glucose-6-
phosphate dehydrogenase and nicotinamide adenine dinucleotide phosphate 
dehydrogenase, hence reducing reactive oxygen species (Zhang et al., 2013). Two 
receptor molecules have been identified for TLQP-21, namely the complement 
component 3a receptor (C3a-R: Hannedouche et al., 2013; Cero et al., 2014; 2016;) and 
the receptor for the globular heads of c1q (gC1q-R: Chen et al., 2013) and involved, with 
TLQP-21, in modulating lipolysis (Cero et al., 2016) and neuropathic pain (Chen et al., 
2013), respectively. While the precise mechanisms involved are not entirely known, there 
is strong evidence that the TLQP-21 may act increasing intracellular calcium in Chinese 
hamster ovary cells (Cassina et al., 2013), microglia (Chen et al., 2013) and cerebellum 
(Severini et al., 2008). The longer form TLQP-62 has been widely investigated in 
hippocampus where it enhances synaptogenesis (Behnke et al., 2017), regulates 
memory formation, and induces both synaptic potentiation (Bozdagi et al., 2008; Lin et 
al., 2015) and neurogenesis (Takker-Varia et al., 2014). It can also cause dorsal horn cell 
hyper-excitability and behavioral hypersensitivity in rats (Moss et al., 2008). No specific 
receptor has been identified so far for TLQP-62.  In ALS, despite the reported evidence 
that VGF expression is modulated in the animal model and humans  (Pasinetti et al., 
2006; Zhao et al., 2008), limited information is available regarding TLQP peptides. We 
have previously reported the involvement of the VGF C-terminal peptides in ALS, 
modulated in the SOD1 mutant mice and patient’s plasma, but exclusively at the final 
disease phase (Brancia et al., 2016). Afterwards, we aimed at specifically investigating 
the role of the TLQP peptides in ALS, by studing their expression and changes (using 
ELISA and immunohistochemistry) in transgenic mice (SOD1-G93A) and the mouse 
motor neuron-like hybrid cell line (NSC-34), as experimental models. In parallel, we also 
investigated, by ELISA, ALS patients’ plasma and primary fibroblast cultures, the latter 
being considered a good cellular model used in human ALS research (Sabatelli et al., 
2015; Yang et al., 2015) and also, contain VGF (Brancia et al., 2016). Moreover, in the 
NSC-34 cells, the neuroprotective role of the TLQP-21 was addressed in parallel with the 
presence of its two known receptors (gC1q-R and C3a-R), examined by both western 




Human subjects  
Subjects of Sardinian descent were studied, including ALS patients (females: n=20, 
males: n=24, age range: 25–85 yrs), and age-matched controls (unaffected by either 
neurological conditions, or diabetes; females: n=20, males: n=26). In patients, ALS 
related mutations were studied as follows: exon 6 of the TARDBP gene, and all five 
coding exons of the SOD1 gene were screened by polymerase chain reaction and 
sequenced using the Big-Dye Terminator v3.1 kit  (Applied Biosystems Inc) and an ABI 
Prism 3130 Genetic Analyzer. A repeat-primed polymerase chain reaction assay was 
used to screen for the GGGGCC hexanucleotide expansion in the first intron of 
C9ORF72 (DeJesus-Hernandez et al., 2011; Renton et  al., 2011). ALS patients studied 
showed either of: TARDBP-A382T mutation (n=16), SOD1-G93A mutation (n=3); 
expansion in the C9ORF72 gene (n=5), or no identifiable ALS-related mutation (n=20). 
The patients’ motor and functional (which incorporates additional assessments of 
dyspnea, orthopnea, and the need for ventilatory support) performance was assessed at 
the time of blood sampling, by at least two experienced neurologists, according to the 
ALS Functional Rating Scale Revised (ALSFRS-R: Cedarbaum et al., 1999). Patients’ 
data (summarised in Appendix A: Table 1A), including: age, gender, genetic mutation, 
ALSFRS-R score and co-morbidity at the time of blood sampling, as well as their clinical 
condition one year later (whether alive, or not, with or without tracheostomy). On the 
latter basis, patients were assigned to either of group I, “early disease stage” (n=25): 
patients who were alive and free of tracheostomy one year after blood sampling; or group 
II, “late disease stage” (n=19): patients who were deceased, or had undergone 
tracheostomy. The present study was approved by the Ethical Committee at the Cagliari 
AOU (“Azienda Ospedaliero Universitaria di Cagliari”), protocol n. 450/09/C.E. All 
patients provided their written informed consent to be part of the study according to the 
Italian legislation.  
 
Human samples  
Blood samples were collected with ethylenediaminetetraacetic acid (EDTA, 1.5 mg/ml), 
rapidly centrifuged (14,000 rpm, 5 min), hence plasma was aliquotted and stored frozen 
(at -80°C). Fibroblast primary cultures were set up using skin biopsies (taken under local 
anaesthesia) obtained from “late disease stage” ALS patients (n=4: two showed a 
heterozygous missense TARDBP-A382T mutation, two showed no identifiable ALS-
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related mutation), and age-matched controls (n=3). Cultures were grown as previously 
reported (Orrù et al., 2016), using high-glucose Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with fetal bovine serum (20% vol/vol) and penicillin/streptomycin 
(10 ml/L of: 10,000 U penicillin + 10 mg/ml streptomycin in 150 mmol/L NaCl). Oxidative 
stress was induced adding sodium Arsenite (SA) to the culture medium (0.5 mmol/L, for 
60 min). For ELISA, cultures were expanded, and four culture plates per patient (or 
control), and per treatment (SA, or no treatment), were separately extracted in phosphate 
buffer saline (PBS: 0.01 mol/L PO4, pH 7.2, 0.15 mol/L NaCl) containing a protease 
inhibitor cocktail (PIC, Sigma-Aldrich P8340, 10 ml/g tissue). Remaining extracts (from 
controls’ explants) were pooled and used for gel chromatography.  
For immunocytochemistry, cells were grown on coverlips, and at least three coverslips 
(per patient/control, and per treatment) were fixed in paraformaldehyde (PFA: 40 g/L in 
PBS, 15 min), permeabilized with cold methanol (5 min), hence Triton X-100 (20 ml/L in 
PBS, 20 min), and rinsed with PBS. Coverslips were immunostained for TLQP peptides, 
and with an HuR antibody (Santa Cruz, Antibody Registry: AB627770, raised in mouse, 
1:500) to label stress granules, while nuclei were counterstained with bisBenzimide 
(Hoechst 33342, 0.5 ug/ml in PBS). 
 
SOD1-G93A mice 
Transgenic B6SJL-TgN(SOD1-G93A)1Gur mice were used, over-expressing human 
SOD1 containing the Gly93 to Ala mutation (Jackson Laboratory, Bar Harbor, ME; stock 
number 002726; housed at the University of Turin animal house facilities). All 
experimental procedures on live animals were carried out in accordance with the 
European Communities Council Directive 86/609/EEC (November 24,1986), and the 
Italian Ministry of Health and University of Turin institutional guidelines on animal welfare 
(law 116/92 on Care and Protection of living animals undergoing experimental or other 
scientific procedures; authorization number 17/2010-B, June 30, 2010). The Ethical 
Committee at the University of Turin approved the study. All possible efforts were made 
to minimize the number of animals used and their suffering. Animal genotyping and 
behavioral testing used to assess disease progression (neurological test, rotarod and 
paw grip endurance tests) were previously described in detail (Boido et al., 2014). 
Transgenic animals were grouped according to age (days postnatal: P) and stage of 
motor dysfunctions (Brancia et al., 2016), as follows: (i) pre-symptomatic (around P45); 
(ii) early-symptomatic (around P90; two repeated deficits for two consecutive times); (iii) 
late-symptomatic (around P120; >20% weight loss and inability to perform tests). Age-
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matched wild type mice were used as controls: groups (iv) through (vi), respectively. 
Male mice were used in all cases, in view of our previous finding of TLQP modulations in 
female rodents along the oestrous cycle (Noli et al., 2014).  
For ELISA and gel chromatography, animals (n=7 per group) were anaesthetized 
(3% isoflurane vaporized in O2/N2O 50:50), hence blood was drawn by cardiac puncture, 
collected in EDTA containing tubes (1.78 mg/ml), and centrifuged (11,000 rpm, 5 min). 
Plasma was aliquotted and stored frozen (-80°C). Upon blood sampling, animals were 
euthanized by cervical dislocation, and spinal cords were dissected. Tissues were 
coarsely minced with a scalpel, collected in tubes with ice-cold PBS containing PIC (10 
ml/g tissue), treated with an Ultra-Turrax tissue homogenizer (Ika-Werke, Staufen, 
Germany, 3 min), hence tubes were heated in a vigorously boiling water bath (10 min), 
and centrifuged (3,000 rpm, 15 min). Supernatants were stored frozen until use (-20°C). 
For immunohistochemistry, mice (n=3 per group) were anaesthetized as above, and 
perfused transcardially with PFA (10 min). The whole spinal cord was removed and post-
fixed in PFA (at 4°C, 2h). Cryosections of cervical and lumbar spinal cord (8 um 
thickness) were immunostained (in single and double immunofluorescence) for TLQP 
peptides, and with an antibody to vesicular acetylcholine transporter (VACht, BIOMOL 
Research lab, Antibody Registry: AB2052813, raised in goat, 1:400) to label cholinergic 
motor neurons.  
  
NSC-34 cells and oxidative stress 
Cells were grown in high-glucose DMEM, supplemented with fetal bovine serum (10% 
vol/vol) and penicillin/streptomycin (as for fibroblasts, see above). For testing, cells were 
plated at a 50,000/ml density in 24-well plates (24h), hence underwent oxidative stress 
by addition of SA (0.5 mmol/L in culture medium, 60 min at 37°C) and measered the 
levels of TLQP-21, NERP-1, NAPP- and APGH-peptides, as well as  VGF N-terminus 
and C- terminus. The effect of TLQP-21, NERP-1 (synthetic, custom produced for us by 
CPC Scientific, Sunnyvale, CA) was assessed by addition to the culture media, in the 
presence / absence of SA, at a range of concentrations (0.1 to 10 nmol/ml). Cell 
proliferation and viability was assessed used a colorimetric method based on the 3-(4,5-
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide reagent (MTT test, Sigma-Aldrich), 
according to the manufacturer’s protocol. Absorbance was measured at 570nm (EnVision 
plate analyzer, Perkin Elmer, Milan, Italy).  For ELISA and gel chromatography, cells 
preparations were extracted with PBS containing PIC (10 ml/g tissue), as described for 
fibroblasts. For immunocytochemistry, preparations grown on glass coverslips were fixed 
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with PFA (10 min), permeabilized with cold methanol (5 min), then with Triton X-100 (10 
ml/L in PBS, 20 min), and rinsed in PBS. Coverslips were immunostained for TLQP 
peptides, and for the TLQP-21 receptors: gC1q-R (Abcam, Antibody Registry: 
AB10675815, raised in rabbit, 1:600), and C3a-R (Abcam, Antibody Registry: 
AB2687440, raised in rabbit, 1:200–1000). A HuR antibody (Santa Cruz, Antibody 
Registry: AB627770, raised in mouse, 1:500), to label stress granules, and a calnexin 
antibody (Sigma-Aldrich, Antibody Registry: AB2069152, raised in mouse, 1:300), to 
label endoplasmic reticulum (ER), were used in double-immunostaining with the TLQP 
antiserum. Cell nuclei were counterstained with bisBenzimide (Hoechst 33342, 0.5 
ug/ml). 
  
TLQP peptide/s antiserum 
The guinea-pig primary antiserum to TLQP peptides, specific for their common N-
terminal portion, previously described in detail (Brancia et al., 2005) was extensively 
used in different organs and tissues (Cocco et al., 2007, D’Amato et al., 2008; Brancia C 
et al., 2010; Noli  et al., 2014; D’Amato et al., 2015; Noli  et al., 2017). Briefly, a synthetic 
peptide corresponding to rat VGF556–564, with the addition of a C-terminal cysteine 
residue, was conjugated via its C-terminus to keyhole limpet hemocyanin (KLH), and 
used for immunizations. See ELISA and immunohistochemistry sections (below), for 
specificity controls relevant to its use in each method.  
 
ELISA  
Competitive ELISA was carried out as previously described in detail (Cocco et al., 2007), 
and the characterization of the TLQP assay are summarized in Table 1, while calibration 
curve is shown in Fig.1. Briefly, multiwell plates (Nunc Thermoscientific, Milan, Italy) were 
coated with the relevant synthetic peptide, hence treated with PBS containing  normal 
donkey serum (90 ml/L), aprotinin (20 nmol/L), and EDTA (1 g/L) for 2 hours. Primary 
incubations (3h) were carried out in duplicate, using TLQP (1:5k), NERP-1 (1:160k; 
Cocco et al., 2007), NAPP (1:100k; D’Amato et al., 2015) as well as N-terminus and C-
terminus (both 1:12k; Cocco et al., 2010) antisera followed by biotinylated secondary 
antibodies (Jackson, West Grove, PA, Antibody registry: AB2340451; 1:10K,1h), 
streptavidin-peroxidase conjugate (Biospa, Milan, Italy, 30 min), and tetrametylbenzidine 
substrate (TMB X-traKem-En-Tec, Taastrup, Denmank, 100 ml/well). Reaction was 
stopped with HCl (1 mol/L) and optical density was measured at 450nm using a 
multilabel plate reader (Chameleon: Hidex, Turku, Finland). Recovery of synthetic 
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peptide (same used for immunization, plate coating and measurement standard) added 
to plasma, or to tissue samples at extraction was >85%.  
 
Gel chromatography  
Plasma samples (human: 2 ml, or a pool from control mice: 1 ml), as well as extracts of 
spinal cord (pooled from control mice: 1.6 ml), NSC-34 cells (2 ml) and fibroblasts (1.2 
ml) were individually loaded onto a Sephadex G-50S column (Sigma-Aldrich, 2 cm2 x 
1m). The column was equilibrated with ammonium bicarbonate solution (50 mmol/L in 
H2O) and eluted with the same buffer (about 0.3 ml/min, using a membrane pump 
running at 5 impulses/min, -4°C). The column was calibrated using a kit (MVGF70, 
Sigma-Aldrich) containing the following molecular weight markers: bovine albumin (66 
kDa), carbonic anhydrase (29 kDa), cytochrome c (12.4 kDa), and aprotinin (6.5 kDa).  
Collected fractions (3 ml) were reduced in volume using a Vacufuge Concentrator 
(Eppendorf, Milan, Italy) and assessed by ELISA. Experiments were carried out in 
duplicate, or in triplicate, depending on sample availability. Overall recovery of loaded 
immunoreactive material/s resulted in an 81–102% range.  
  
Detection of TLQP peptides in tissues and cells 
TLQP antiserum (1:600 to 1:800) were diluted with PBS containing normal donkey serum 
(30 ml/L, from a pool of  >5 animals) and NaN3 (0.5 g/L), with the addition of normal 
mouse serum (30 ml/L: mouse tissue sections only). Primary incubations were carried 
out at room temperature, either overnight (16h: mouse spinal cord sections), or for 4 h 
(fibroblast and NSC-34 cell cultures). For double-labelling, the relevant primary 
antibodies were mixed and similarly incubated (see specific part). Sites of primary 
immune reaction were revealed using secondary IgG preparations absorbed against 
serum proteins from multiple species (Jackson Immunoresearch Laboratories, West 
Grove, PA), at a 2 to 10 mg/L concentration (in PBS, 1h at room temperature). As 
appropriate, either of the following were used (1:200-300): (a) Cyanin 3.18 conjugated 
donkey anti-guinea pig IgG (Antibody registry:AB2340460), (b) Cyanin 3.18, or Alexa488 
conjugated anti-mouse IgG (Antibody registry: AB2340460 and AB2341099, 
respectively), (c) a mixture of “a” and “b” above, (d) Cy3 conjugated anti-rabbit IgG 
(Antibody registry: AB 2307443) (e) Alexa488 conjugated donkey anti-sheep IgG 
(Antibody registry: AB 2340754). Routine controls included: substitution of each antibody 
layer, in turn, with PBS; the use of pre-immune, or non-immune sera; the use of 
inappropriate secondary antibodies. Pre-absorption of the TLQP antiserum with the 
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relevant (unconjugated) peptide (up to 100 mmol/L) resulted in virtually complete 
prevention of  the corresponding labelling. Slides were coverslipped, and culture 
coverslips were mounted on slides, using Glycerol-PBS (1:2) containing NaN3 (0.2 g/L). 
Preparations were observed and photographed using a BX51 fluorescence microscopes 
(Olympus, Milan, Italy) equipped with a Fuji S3 Pro digital camera (Fujifilm, Milan, Italy).  
 
Western blot of TLQP-21 receptors  
NSC-43 cell preparations were lysed in 2% sodium dodecyl sulfate (20g/L, min), and a 
sample (10 ul) was set aside to assess protein concentration (BCA assay, Thermo 
Scientific). Loading buffer (75 mmol/L tris-hydrogen chloride buffer, pH 6.8, containing 
200 ml/L glycerol, 0. 4g/L% SDS, 5% β-mercaptoethanol, 0.001% bromophenol blue) 
was added to the extract, hence tubes were heated in a vigorously boiling water bath (3 
min). Samples (containing about 15 μg proteins each) were loaded onto 4–20%  gradient 
SDS (sodium dodecyl sulphate)-polyacrylamide gels and blotted onto polyvinylidene 
fluoride membranes (Hybond-P, Amersham). Membranes were blocked with 5% non-fat 
dry milk (50 g/L, 1h, in PBS) and incubated overnight (16h, at 4°C) with either of the 
TLQP-21 receptor antibodies (see above: NSC-34 cell cultures). On the following day, 
membranes were incubated with horseradish-peroxidase-conjugated anti-rabbit IgG 
(Invitrogen, Life Technologies, 1:5000, 1h), hence revealed using a chemiluminescent 
substrate (Euroclone, SpA, Pero, Milan). A rabbit anti-actin antibody (Sigma-Aldrich, 
Antibody Registry: AB476697, 1:1000) was used to confirm an equal protein loading. 
Runs were carried out in triplicate in different days.  
 
Statistical analyses  
Statistical analyses were carried out using the StatistiXL software. For each experimental 
set, the normality of data distributions was preliminary checked using the Goodness-of-fit 
test. Resulting p values were  >0.05 in all cases, hence the following parametric tests 
were applied. In case of unequal variance, the Welch's t-test (tw-test) was carried out, 
otherwise the two-tailed Student’s t-test with pooled variances was applied. Linear 
regression analysis was used to estimate possible correlations between plasma TLQP 
peptides, versus ALSFRS-R rating or the patients’ age. In all cases, p-values <0.05 were 





RESULTS   
 
TLQP peptides in human  
In plasma, levels of TLQP peptide immunoreactivity were roughly 80–90 pmol/ml in 
control subjects. A distinct, reduction in plasma TLQP peptides was seen in ALS patients 
(Fig. 2A), already in the early stage (mean  ES, controls: 87.2  4.3; patients: 75.1  4.0, 
twtest: p<0.05, DF=65.4,) as also in the late stage (patients: 73.5  3.8, twtest: p<0.05, 
DF: 57.3). Data are expressed as percentage of the control samples (100%). In gel 
chromatography, the following profile of TLQP immunoreactivity was revealed  (Fig. 2B): 
(i) a major peak at a ~ 7–8 kDa elution position compatible with TLQP-62 (c) (ii) a broad 
peak in the  ~6.5–4 kDa region probably corresponding with the TLQP -42 and -30 forms 
(d–e), and a lower peak at ~ 2–3 kDa compatible  with  TLQP-21 (f). Two larger forms 
were also found close to the void volume, at about 66 and 14–15 kDa elution positions 
may compatible to the VGF precursor (peak “a”) and NAPP-129 (peak “b”), respectively, 
both including the internal TLQP sequence. The sequences of the above TLQP peptides 
are summarized in Fig. 3.  No correlation was found between patients’ plasma TLQP 
peptide levels and their corresponding ALSFRS-R score, age, or sex (Fig. 2C–E). In 
fibroblasts (Fig. 2F–I) a significant reduction in TLQP peptide/s immunoreactivity 
(pmol/ug; controls: 0.35  0.04, ALS: 0.24  0.02, t-test: p<0.05, DF=19) was shown in 
culture extracts from ALS patients compared to controls (Fig. 2F). TLQP peptide/s 
immunoreactivity was revealed in a region of cytoplasm close to the nucleus, bona fide 
the Golgi area, as previously shown (Brancia et al., 2016) and in agreement with the role 
of VGF as precursor of secretory products (Brancia et al., 2005). In both ALS patients 
and controls (Fig. 2G,H; respectively) cytoplasmic stress granules appeared after SA 
treatment as previously reported (Orrù et al., 2016). Such granules were not labelled by 
the TLQP antibodies (Fig. 2I). The molecular forms seen upon gel chromatography were 
broadly comparable to those found in plasma (data not shown).  
  
TLQP peptides in mice   
In the cervical spinal cord of wild type mice of all ages studied, TLQP peptides were well 
represented in large and medium size perikarya in laminae VIII and IX, the majority 
surrounded by the VAChT staining, hence identified as motor neurons (Fig. 4A, white 
arrows) while their levels (through ELISA) were in a range of 100–250 pmol/g. Instead, in 
the mutant mice, the TLQP immunoreactivity was significantly decreased, through both 
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IHC (Fig. 4A) and ELISA in the pre-symptomatic stage (158.7 ± 15.1 and 46.6 ± 20.4, 
wild type vs. SOD1, t-test: p<0.005, DF=9), remaining down regulated up to the late-
stage (WT:186.8 ± 10.6, SOD1: 153.5 ± 19.9, t-test: p<0.05, DF=10) (Fig. 4B). Lumbar 
and cervical spinal cords were analysed in parallel showing similar immunostaining 
profiles in both IHC and ELISA. The molecular forms recognised by the TLQP antiserum 
were comparable to those observed in human samples, including peacks compatible with 
TLQP-62,-42,-30,-21 (peaks c, d, e, f) and the two peaks, “a” and “b”, may compatible 
with the VGF precursor and NAPP-129, respectively (Fig. 4C). In all wild type mice, 
plasma concentrations of TLQP peptides ranged between 170 and 200 pmol/ml, while 
they were significantly decreased in SOD1 mutant mice at the pre-symptomatic stage 
(WT: 170.5 ± 17.8, SOD1: 125.7 ± 8.8, t-test: p<0.05, DF=10), remaining reduced in the 
late stage (WT: 171.5 ± 9.8, SOD1: 132.3 ± 12.1, t-test: p<0.05, DF=10) (Fig. 4D).  Gel 
chromatography applied to the mouse plasma revealed similar forms observed in human 
and mouse spinal cord hence it was not shown.  
  
TLQP peptides and NSC-34 cells  
TLQP immunoreactivity was found in the growth cones and axons of NSC-34 cells, as 
well as in their cytoplasm in a para-nuclear location suggestive of its abundance in the 
bona fide Golgi area (Fig. 5A left panel). No co-localization was found with markers of the 
ER (data not shown). Upon treatment with SA, to induce oxidative stress, cells mostly 
lost their axons and growth cones changing to a round shape while TLQP peptides 
manteined their cytoplasmic localization (Fig 5A, middle panel). No TLQP-
immunoreactivity was detected in stress granules (Fig 5A, right panel). A significant 
decrease of TLQP peptides content (pmol/ug total protein; Fig. 5B) was found in SA 
treated cells (naïve: 0.199  0.04, treated: 0.094  0.01, twtest: p<0.05, DF=9). Addition of 
synthetic TLQP-21 (1nmol/ml) to culture media of SA treated cells significantly increased 
cell viability, compared to the SA treatment only (82.5% vs. 74.7%, p<0.05; Fig. 5C). 
Several VGF derived peptides were measured in naive and SA stressed cells. Further to 
TLQP peptides, these included NERP-1, NAPP- and APGH-peptides, as well as VGF N-
terminus and C- terminus related peptides. Only TLQP and NERP-1 peptide/s showed a 
significant change (reduction) in stressed cell cultures, hence were tested. However, 
addition of  synthetic NERP-1 to the cell culture medium did not result in any detectable 
change in cell viability (data not shown).  When we used the antibodies against the two 
TLQP receptors, the gC1q-R antibody showed a labelling in the nucleus with a feeble 
immunostaining into the cytoplasm (Fig. 5D), as expected (Soltys et al., 2000) while a 
 14 
weak staining only was revealed  for C3a-R. The presence of gC1q-R (predicted 
molecular weight: 33kD) was confirmed by western blot analysis (Fig. 5E). NSC-34 
extracts revealed approximately the same MW forms observed in human and mouse 





We demonstrate here a downregulation of TLQP peptides in both stressed NSC-34 cells 
and untreated fibroblast cultures from ALS patients, as well as in motor neurons of SOD-
1 mice before the onset of significant muscle weakness. In plasma, TLQP peptides were 
also reduced from the early clinical stages in ALS patients, and so were in the earliest 
stage studied in SOD-1 mice (pre-symptomatic stage). Hence, plasma TLQP peptides 
may have a value as possible biomarkers in the screening or diagnosis of suspected ALS 
patients.  
 
TLQP peptides as blood biomarkers  
The identification of potential biomarkers sensitive to the progression of disease is one of 
the  present goals of ALS research.  In SOD-1 mice, the reduction of TLQP peptide/s we 
observed in both plasma and motor neurons at the earliest, pre-symptomatic stage 
suggests that plasma changes may not only parallel, but also reflect early changes 
occurring in motor neurons. Hence, peptides of the overall TLQP family may show 
promise as indicators for early diagnosis of ALS. In fact, measurement of most 
neurotrophic factors, including BDNF (Tremolizzo  et al., 2016), failed to selectively 
detect ALS patients and changes at an early phase (Turner et al., 2009). In a previous 
study, we revealed changes in peptides derived from a different part of VGF, namely the 
region encompassing the C-terminal end of the VGF precursor (Brancia et al., 2016). 
VGF C-terminus peptides also showed significant changes in ALS patients, but only at 
the  advanced clinical stage (Brancia et al., 2016). Hence, it is conceivable that other 
VGF derived peptides, including those related to the VGF C-terminus, may decrease 
upon an extensive neuronal damage, while TLQP peptides are reduced at an earlier 
stage of initial cellular damage or breakdown. While further studies will be required, with 
the precise identification of the molecular forms involved, one might suggest that TLQP-
21 and other related peptides, i.e TLQP-62, could be most prominently involved in the 
overall changes found in the present paper. The TLQP-62 peptide, deserves a special 
mention, because, since it extends from the TLQP sequence to the full C-terminus of the 
VGF precursor, it is also recognised and measured by VGF C-terminus assay (Brancia et 
al, 2016).  Moreover, since the Sardinian population has a high predominance of 
TARDBP mutation (Chiò et al., 2011), as reflected in our cohort of patients, we were not 
able to study any correlation between TLQP levels and specific ALS mutation/s. While 
future studies will be done by us to investigate if the reduction of TLQP peptides is 
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peculiar for ALS, schizophrenia induced by phencyclidine has not produced any TLQP 
changes in the rat blood (Noli et al., 2017).  
 
TLQP peptides are reduced in ALS tissues  
TLQP peptides were reduced in spinal cord motor neurons of SOD1-G93A mice, in SA-
stressed NSC-34 cells, as well as in fibroblast cultures from ALS patients. Interestingly, 
the latter patients showed a TARDBP mutation, which has also been proposed to induce 
cell death through oxidative stress (Duan et al., 2010; Braun et al., 2011; Zhan and 
Tibbets, 2015). Altogether, TLQP peptide/s changes we observed probably occurred in 
connection with oxydative stress and ensuing pathophysiological mechanisms. This way, 
the TLQP alterations occurring in the spinal cord of pre-symptomatic SOD1 mice may be 
relevant part of, or respond to the early modifications triggering the waterfall of events 
that cause motor neuron degeneration. It is worth noting that TLQP peptides were 
localized in the bona fide Golgi area as well as in growth cones and axons (Chevalier-
Larsen and Holzbaur, 2006). Golgi fragmentation has been shown to be associated with 
ALS hallmarks, and to occur at an early, preclinical stage in both ALS patients 
(Maruyama et al., 2010), and SOD1 mice (Vlug et al., 2005; Van Dis et al., 2014). In the 
same mice, defects in retrograde transport, from the muscle cells to the cell body of 
motor neurons, have been suggested to be one of the earliest visible alterations (Ligon et 
al., 2005).  
 
TLQP-21 protects neuronal cells from oxidative stress  
We here reported that the TLQP peptides, localized in the cytoplasm and growth 
cones/axons of the NSC-34 cells, decreased in response to oxidative stress, while the 
TLQP-21, when added in the medium, is able to protect the cells from the death. The 
other VGF peptides tested in the stressed NSC-34 cells were not reduced, or, if they 
were, did not protect the cells from the death (as in the case of the NERP-1). Since the 
presence of both TLQP peptides and  gCq1-R within the NSC-34 cells, we could 
speculate that the neuroprotection could be due to mechanisms linked to their 
relationship. Actions of TLQP-21 via the gC1q-R receptor has been shown to be 
implicated in hypersensitivity in the spinal cord dorsal horn (Chen et al., 2013). The 
gC1q-R is an ubiquitous protein of 33 kDa initially identified and characterized as a 
receptor for the globular heads of the complement activation component C1q 
(Ghebrehiwet et al., 1994) and involved in the inflammatory response (Peerschke and 
Ghebrehiwet, 2007). In spinal cord motor neurons of SOD1 mice, it was found to be 
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detectable before the appearance of the clinical symptoms (Heurich et al., 2011) with a 
major expression at the late stage (Lee et al., 2013). TLQP-21 has been previously 
reported, as mentioned, to prevent apoptosis induced by oxidative stress in both human 
(Zhang et al., 2013) and rat cells (Severini et al., 2008). All together these pieces of 
evidences highly suggest an involvement of TLQP-21-gC1q-R complex in the increased 
cell viability that we reported here, none the less, studies are warranted to  investigate 
TLQP-21 activity on motor neurons in a variety of conditions. The gC1q-R is also 
expressed in fibroblasts (Bordin and Costa, 1998), where it might exert a protective 
action against oxidative stress (McGee and Baines, 2011). Hence, fibroblast cultures 
may be a further means to address the mechanisms implicated in TLQP-21 bioactivity, 
and its possible value in ALS.   
Collectively, our study suggests that the TLQP family, including both TLQP-21 and 
TLQP-62, respond early to oxidative stress, and could be of value as a biological 
diagnostic index for ALS.  The TLQP-21 peptide might be of some relevance to prevent 
or reduce motor neuron death. Further studies may be of interest, to address the possible 
relevance of TLQP peptides other than TLQP-21. TLQP-62 has so far better studied, and 
has been shown to have a role in neurogenesis (Takker-Varia et al., 2014). Interestingly, 
in ALS patients, where impaired glucose tolerance has been reported (Sun et al., 2015), 
certain metabolites modulated in plasma are indicative of alterations in both 
mitochondrial activity and carbohydrate/lipid metabolism associated with neuronal 
changes (Lawton et al., 2012). Since TLQP-21 is a metabolic peptide acting on energy 
and lipolysis mechanisms (Bartolomucci et al., 2006), and TLQP-62 is a hypoglycaemic 
agent (Petrocchi-Passeri et al., 2015), we could speculate that both peptides could be 
possibly involved in the energy mechanisms that contribute to motor neuron 
degeneration (Dupuis et al., 2004). In conclusion, although currently there are no 
applicable blood diagnostic tests and pharmacological treatments for ALS, research on 
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Fig. 1. Calibration curve. The standard curve was obtained using a range of 
concentrations of the “reference” peptide in solution (VGF556–564) and a fixed amount of 
the same peptide onto the well, competing for the TLQP antibody, OD: optical density; 
pmol/ml:picomoles/milliliters.  
 
Fig. 2. TLQP peptides in human. Plasma levels of TLQP peptides (A). The levels of 
TLQP peptides in the early and late stage of the ALS patients (n= 25 and 19, 
respectively) are both reduced, when compared with the controls (n=46); percentage of 
reduction: 14 and 16, early and late stage, respectively, twtest: p<0.05. Data are 
expressed as percentage of the control samples (100%). Chromatographic analysis 
coupled with ELISA (B). The following molecular forms are recognised by the TLQP-
antiserum:  a. ~66kDa, probably the VGF precursor; b.~15kDa compatible to NAPP-129, 
as well as: c. ~7–8kDa, d–e.~6.5–4 kDa, f.~2–3 kDa, compatible to TLQP -62, -42, -30 
and -21, respectively. Arrows in the top indicates the molecular weight markers, pmol: 
picomoles. ALS Functional Rating Scale Revised (ALSFRS-R) vs. TLQP peptides levels 
(C). There is not a statistically significant linear relationship (p≤0.427, R=0.124) between 
TLQP peptides levels and the ALSFRS-R values; pmol/ml: picomoles/milliliter. Patient’s 
ages vs. TLQP peptides levels (D). We observe a no statistically significant linear 
relationship (p≤0.507; R=0.103) between TLQP peptides levels and patient’s ages. TLQP 
peptides levels in female and male ALS patients (E). A no significant difference is found 
between males and females ALS patients (p>0.05). TLQP in fibroblasts (F–I). TLQP 
peptides are reduced (F) in naïve ALS patient derived cells (n=4) compared to the 
corresponding controls (n=3; 31% of controls; t-test: p<0.05) pmol/ug: 
picomoles/micrograms. TLQP peptides are present in specific cytoplasm structures, 
probably the Golgi area, in cells from controls as well as ALS patients (G and H, 
respectively; red-orange, Cy3), either before (H) or after the treatment with SA (I), that 
produces visible stress granules (revealed with anti HuR, green, Alexa-488). The nuclei 
are revealed in Blue (Hoechst 33342).  
 




Fig. 4. TLQP peptides in mice.  TLQP peptides in cervical motor neurons (A). TLQP 
peptides immunoreactivity (Cy3, red) is localized in a large number of perikarya of the 
ventral horns in wild type mice in the age of the pre-symptomatic and late stage of 
transgenic mice. These cell bodies are identified as motor neurons using VAChT 
antibody (Alexa-488, green). Instead, in the SOD1-G93A-mice, the TLQP 
immunoreactivity is weak visible in a minor number of cells already in the pre-
symptomatic stage and remains reduced also in the late stage (n=3 per genotype). 
Levels of TLQP peptides in cervical spinal cord (B). TLQP levels are significantly 
decreased in mutant mice (vs the corresponding wild type) already in the pre-
symptomatic phase (percentage of decrease: about 70; p<0.005) as well as in the late 
stage (18%; p<0.05). Data are expressed as percentage of the control samples (100%), 
n=7 per genotype. Chromatography analysis coupled with ELISA in spinal cord (C). 
Different molecular forms are recognised by the TLQP antiserum: a.~66kDa, compatible 
to the VGF precursor; b.~15kDa compatible to NAPP-129, and the peaks:  c.~7–8kDa, 
d.~5kDa, e.~3kDa, and f. ~2 kDa, compatible to TLQP -62, -42, -30 and -21, respectively. 
Arrows in the top indicates the molecular weight markers; pmol:picomoles. Levels of 
TLQP peptides in plasma (D). TLQP levels are significantly decreased in mutant mice vs 
wild type already in the pre-symptomatic phase (26%; p<0.05) as well as in the late stage 
(23%; p<0.05). Data are expressed as percentage of the control samples (100%), n=7 
per genotype.  
 
Fig. 5. TLQP peptides in NSC-34 cells. TLQP immunolocalization (A). TLQP peptides 
(Cy3, red-yellow,) are found within the cytoplasm, probably in the Golgi area as well as in 
the axons and growth cones (left panel). When treated with Sodium Arsenite (SA), the 
cells lose their growth cones changing to a round shape (nucleus revealed in Blue: 
Hoechst 33342) and TLQP peptides are present exclusively within the cytoplasm (middle 
panel) and not visible in the stress granules (revealed with anti HuR, ALEXA488, green; 
right panel). TLQP levels (B). A significant TLQP peptides decrease is seen (B) in the SA 
treated compared to the naïve cells (about 53%, p<0.05). Pmol/ug prot tot: 
picomoles/micrograms of total protein. MTT viability test (C). The NSC-34 viability 
increases when the cells are treated with SA together with TLQP-21, compared to the 
treatment with the SA only (about 83% vs. 75%, p<0.05). TLQP-21 alone is not able to 
produce any effect. The gC1q-R immunoreactivity (D, E). The gC1q-R antibody stains the 
nucleus as well as weakly the cytoplasm (D, Cy3 red-yellow), and also labelled a form of 
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1 67 M 25 TDP-43  A382T  
2 66 F 19 TDP-43  A382T  
3 81 F 30 nd MDS 
4* 39 F 22 TDP-43  A382T  
5 56 F 43 SOD1  
6* 66 F 14 TDP-43  A382T  
7 82 M 21 nd  
8 72 F 22 TDP-43  A382T  
9* 53 M 28 nd  
10* 72 M 11 C9ORF expansion  
11 48 M 26 TDP-43  A382T  
12* 64 M 27 nd  
13 56 M 41 C9ORF expansion DVT  
14 71 M 42 SOD1  
15* 55 M 21 TDP-43  A382T  
16 64 F 38 SOD1  
17 78 M 17 TDP-43  A382T  
18* 42 F 30 nd  
19 53 F 31 nd  
20 65 F 38 C9ORF72 expansion  
21 70 M 15 nd  
22* 69 M 6 TDP-43  A382T  
23 70 F 31 TDP-43  A382T psychosis 
24* 82 M 23 TDP-43  A382T  
25* 76 F 20 TDP-43  A382T  
26* 61 M 35 nd  
27 45 M 41 TDP-43  A382T  
28 53 F 25 nd  
29* 64 M 30 nd  
30 76 M 32 nd  
31* 64 M 17 nd  
32* 53 M 37 nd  
33 72 M 35 TDP-43  A382T  
34 58 M 33 ndr 
 
35 52 M 41 C9ORF72 expansion  
36 67 M 16 nd K colon 
37* 72 F 23 C9ORF72 expansion 
 
38* 74 F 32 nd  
39 67 F 21 TDP-43  A382T Sjögren syndrome 
40 74 F 21 nd 
 
41* 59 F 27 nd  
42* 64 F 16 nd  
43* 63 F 0 nd  
44 65 M 32 TDP-43  A382T Parkinsonism 
 
* = Late stage of ALS disease; nd: not determined; DVT:deep vein thrombosis; MDS: Myelodysplastic syndrome 
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on of peptide producing 50% inhibition of the maximum signal (picomoles/milliliters); 10 
CV1 and CV2: intra- and inter-assay variation, respectively; r: rat; h: human 
1“reference” peptide used for immunization, plate coating, and standard. *Arginine (R): 
residue added at the peptide N-terminus, to mimic its extended sequence within the 
VGF precursor. The cross-reactivity (CR) of each peptide is expressed compared to 
the “reference” peptide, a >100% reactivity is indicated for the authentic TLQP-21 that 15 
is more reactive compared to the reference one. CV1: mean values of six different 
known concentration of TLQP calibrators (500pmol/ml, 50pmol/ml, 5pmol/ml, 
0.5pmol/ml, 0.05pmol/ml, 0.005pmol/ml; 8 replicates). CV2: three known calibrators 
(50pmol/ml, 5pmol/ml, 0.5pmol/ml; 10 independent experiments, in duplicate).  
Assay Peptide IC50 CV1 % CV2% CR% 
      
TLQP rVGF556-564
1
 8 2-3 7-3 100 
 rVGF555-564(R-TLQPPASSR)*    3.5 
 rVGF557-564(-LQPPASSR)    20 
 rVGF556-565(TLQP11)    122 
 rVGF556-576(TLQP21)    183 
 hVGF554-577(TLQP24)    65 
 30 
Figure 1 
 
 31 
Figure 2 
 
 32 
Figure 3 
 
 33 
Figure 4 
 
 34 
Figure 5 
 
 
